Clinical Scorecard: Impact of Systemic Treatments for Advanced Melanoma on the Risk of Mesenteric Panniculitis: Are BRAF/MEK Inhibitors a Contributing Factor?
At a Glance
Category
Detail
Condition
Advanced melanoma and associated risk of mesenteric panniculitis (MP)
Key Mechanisms
BRAF/MEK inhibitors (BRAFi/MEKi) and immune checkpoint inhibitors (ICI) modulate immune response and cancer genomics, potentially inducing systemic and organ-related toxicities including panniculitis
Target Population
Patients with advanced melanoma undergoing first-line systemic treatment with BRAFi/MEKi or ICI
Care Setting
Oncology and dermatology clinical settings with access to CT imaging for monitoring
Key Highlights
BRAFi/MEKi and ICI therapies have significantly improved survival in advanced melanoma but carry distinct toxicity profiles.
Mesenteric panniculitis is a rare, benign inflammatory condition of mesenteric fat that can be incidentally detected on CT imaging and may mimic malignancy.
This retrospective study analyzed 490 melanoma patients treated with BRAFi/MEKi or ICI to investigate the incidence of MP and its imaging characteristics.
Guideline-Based Recommendations
Diagnosis
Use portal venous phase CT imaging to identify MP characterized by unilocular mesenteric mass with small nodules, increased fat density (-60 to -40 HU), and a fibrotic rim (<3 mm).
Differentiate MP from mesenteric lymph node metastases or peritoneal carcinomatosis by noting multilocular nodules >10 mm, omental caking, fat stranding, and ascites.
Confirm diagnosis with clinical data, follow-up imaging, and histopathology if biopsy is available.
Management
Monitor patients receiving BRAFi/MEKi or ICI for signs of MP, especially if abdominal symptoms develop.
Avoid misinterpretation of MP as malignancy to prevent unnecessary interventions.
Monitoring & Follow-up
Perform baseline full-dose CT imaging within 3 months prior to therapy start and follow-up CT imaging at least 30 days after therapy initiation.
Use imaging follow-up to assess progression or resolution of mesenteric lesions.
Risks
BRAFi/MEKi treatment may increase risk of panniculitis including MP due to immune activation.
MP can mimic or disguise underlying malignancy, posing diagnostic challenges.
Patient & Prescribing Data
490 advanced melanoma patients treated with first-line BRAFi/MEKi (106 patients) or ICI (384 patients)
BRAFi/MEKi regimens included dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib; ICI regimens included nivolumab, pembrolizumab, ipilimumab, and combinations. Median patient age ranged from 58 to 62 years with majority stage IV disease.
Clinical Best Practices
Ensure baseline and follow-up CT imaging to detect MP and distinguish it from metastatic disease.
Interpret imaging findings in context of clinical presentation and treatment type to avoid misdiagnosis.
Consider immune-related adverse effects including panniculitis when evaluating new abdominal symptoms in melanoma patients on BRAFi/MEKi or ICI.
Use multidisciplinary approach involving radiologists and oncologists for accurate diagnosis and management.
by Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, Marcel Opitz, Denise Bos, Lisa Zimmer, Selma Ugurel, Johannes Haubold, Dirk Schadendorf, Elisabeth Livingstone, Benedikt M. Schaarschmidt
